Pre-treatment risk assessment of women with endometrial cancer: differences in outcomes of molecular and clinical classifications in the Slovenian patient cohort
, , , , , , y | 17 sept 2021
Acerca de este artículo
Article Category: Research Article
Publicado en línea: 17 sept 2021
Páginas: 76 - 82
Recibido: 13 may 2021
Aceptado: 20 ago 2021
DOI: https://doi.org/10.2478/raon-2021-0036
© 2022 Jure Knez, Monika Sobocan, Urska Belak, Rajko Kavalar, Mateja Zupin, Tomaz Büdefeld, Uros Potocnik, Iztok Takac, published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Figure 1
Analysis of surgical treatment of women based on ESGO Clinical Risk Group assesment. SLN – sentinel lymph node biopsy, LND - lymphadenectomy
| ESGO integrated molecular risk | Total number of women | Open surgery | Laparoscopic | SLN | LND | Unilateral SNB and contralateral LND | No LN treatment |
|---|---|---|---|---|---|---|---|
| Low risk | 22 (56.4%) | 2 (5.1%) | 20 (51.3%) | 18 (46.2%) | 0 | 0 | 4 (10.3%) |
| Intermediate | 4 (10.3%) | 0 | 4 (10.3%) | 3 (7.7%) | 1 (2.6%) | 0 | 0 |
| HIR | 3 (7.7%) | 1 (2.6%) | 2 (5.1%) | 0 | 2 (5.1%) | 1 (2.6%) | 0 |
| High | 9 (23.1%) | 5 (12.8%) | 4 (10.3%) | 2 (5.1%) | 5 (12.8%) | 2 (5.1%) | 1 (2.6%) |
| Advanced | 1 (2.6%) | 1 (2.6%) | 0 | 0 | 0 | 0 | 1 (2.6%) |
Risk assessment
| Number of patients (%) | ||
|---|---|---|
| Low risk | 21 (53.8%) | |
| Intermediate risk | 5 (12.8%) | |
| High-intermediate risk | 2 (5.1%) | |
| High risk | 10 (25.6%) | |
| Advanced metastatic | 1 (2.6%) | |
| Low risk | 22 (56.4%) | |
| Intermediate risk | 4 (10.3%) | |
| High-intermediate risk | 3 (7.7%) | |
| High risk | 9 (23.1%) | |
| Advanced metastatic | 1 (2.6%) |
Characteristics of patients with multiple molecular classifiers
| Age at time of diagnosis | Multiple-classifier EC | POLE variant | Tumor type | FIGO stage | Lymphovascular invasion | Clinical risk assessment | |
|---|---|---|---|---|---|---|---|
| 76 | POLEmut and p53abn | P286R | endometrioid | IIIC2 | Yes | High | |
| 75 | POLEmut and p53abn | P286R | carcinosarcoma | IB | Yes | High | |
| 70 | MMRd and p53abn | wild-type | endometrioid | IA | No | Low | |
| 87 | MMRd and p53abn | wild-type | endometrioid | IIIB | Yes | High | |
| 53 | POLEmut and p53abn | P286R | endometrioid | IA | No | Low | |
| 52 | POLEmut and p53abn | P286R | endometrioid | IA | No | Intermediate |
Patient characteristics
| 65.2 years (min 32 – max 86) | ||
| 31 (17–43) | ||
| Parity (median, range) | 2 (0–5) | |
| Spontaneuos abortion (median, range) | 0 (0–2) | |
| Pre-menopausal | 5 (12.8%) | |
| Post-menopausal | 34 (87.2%) | |
| CA125 (n = 32) | 136.3 (min 2 – max 2084) | |
| CEA (n = 32) | 3.4 (min 2 – max 17) | |
| IA | 21 (54%) | |
| IB | 8 (20.5%) | |
| II | 1 (2.6%) | |
| IIIA | 2 (5.1%) | |
| IIIB | 2 (5.1%) | |
| IIIC1 | 3 (7.7%) | |
| IIIC2 | 1 (2.6%) | |
| IV | 1 (2.6%) | |
| Type 1 | 36 (92.3%) | |
| Type 2 | 3 (7.7 %) | |
| POLEmut | 1 (2.6%) | |
| MMRd | 13 (33.3%) | |
| NSMP | 22 (56.4%) | |
| p53abn | 3 (7.7%) | |